We are excited to announce that our client, EF Hutton, a division of Benchmark Investments, LLC, has successfully closed the underwritten public offering on behalf of Bone Biologics Corporation (NASDAQ: BBLG). This transaction is a testament to the relentless dedication and tireless work of all parties involved, especially the efforts of our exemplary legal team in collaboration with EF Hutton.
